Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Lampsy Health

Lisbon spin-off selling a contactless AI bedside lamp that detects night-time epileptic seizures and alerts caregivers.

Lisbon, Portugal, EuropeMedTech & devices, Epileptic seizure detectionPortugal 2026 (Startup World Cup Portugal, Unicorn Factory Lisboa, 17-18 June 2026) – qualification reported by RTP Geração Digital
Stage
Pre-seedAI at the core
Product
On the marketFirst customers
Funding raised
$680Kdisclosed
Founded
20242 years ago
Founders
3Vicente, Leonor…
Global score
4.5Grade DRank 63 of 151

Overview

A spin-off from Instituto Superior Técnico and Instituto de Telecomunicações, Lampsy Health is developing a smart lamp that detects epileptic seizures, especially at night, and alerts caregivers.

Traction

First customers

Lamp on sale in the EU ("Order Now"), validated by European hospitals according to the company; number of users not published.

Market

Epilepsy monitoring devices

Nocturnal seizures are a major safety concern for people with epilepsy and their families, and many patients refuse wearables at night. Contactless bedside monitoring offers a more acceptable alternative. Today families pay out of pocket; scale requires hospital endorsement, insurer or public reimbursement, and medical-device certification. The niche is small but clinically meaningful.

Addressable market

2025
$0.7B
2030
$0.9B
+5.2% a year

Epilepsy monitoring devices: $0.662bn in 2025, +5.2%/year, $0.85bn in 2030 (Global Market Insights); seizure-detection wearables valued at $1.2bn by MarketIntelo.

Customers

People with epilepsy and their families, epilepsy centres, care homes and residential facilities

Who signs the cheque

Families (out of pocket), hospitals/epilepsy centres recommending devices, insurers and public payers (potential)

Geographies

  • Portugal
  • European Union

Drivers

  • Safety need for night-time seizure detection
  • Patient preference for contactless over wearable monitoring
  • Growth of home-based remote monitoring

Headwinds

  • Medical-device certification and clinical evidence
  • Limited reimbursement
  • Narrow niche and little capital

The epilepsy monitoring device market is estimated at $0.66bn in 2025 (+5.2%/year) according to Global Market Insights; seizure detection wearables are valued at $1.2bn by MarketIntelo.

Scalability 5/10. Consumer device that can be sold online in the EU, but hardware and medical validation.

Market source: gminsights.com

Technology

Category

Medical device – contactless monitoring with AI

AI at the coreMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

A bedside lamp embeds sensors whose signals are analysed by AI to detect seizures without contact and alert caregivers. The company claims 99% accuracy (company figure).

Moat

Moderate: labelled seizure data from hospital validation and a consumer-friendly form factor; certification would raise barriers.

Differentiation

Contactless and unobtrusive versus wrist-worn or mattress devices.

Integration points

  • Remote patient monitoring and care-coordination platforms
  • Epilepsy centre follow-up programmes
  • Insurer home-care programmes
  • Smart-home/caregiver alert apps

Depends on

  • Clinical validation and MDR status
  • Caregiver alert infrastructure (apps, telecom)
  • Hardware manufacturing

Use of AI

AI analyzes the lamp's sensor signals to detect epileptic seizures without contact and alert caregivers.

Product in detail

Bedside lamp with sensors and AI for contactless seizure detection (claimed accuracy of 99%, company figure).

Business

Model
Direct device sales in the EU ('Order Now'); potential subscription for alerting.
Revenue logic
Per-device sale (price not disclosed), possibly plus monitoring subscription.
Go-to-market
Online sales and hospital validation; KPMG/EIC-supported programme; prizes for awareness.

Next milestones

  1. Publish clinical validation results
  2. Obtain/confirm medical-device certification
  3. Sign a reimbursement or insurer pilot

Key risks

  • Regulatory status
  • Unpublished user numbers
  • Small niche

Opportunities

4 found in the network

Concrete moves for Lampsy Health inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 2
  • Investors 1
  • Peers 1

Distribution2

A channel or customer base to reach together

Reach epilepsy-surgery centres through Neurosoft's clinical network

Neurosoft works with epilepsy surgery teams for its soft ECoG electrodes; these centres follow patients before and after surgery who need home seizure monitoring. A referral arrangement gives Lampsy hospital endorsement and Neurosoft longitudinal home seizure data relevant to its research.

25%confidence

Evidence from the records

  • “first-in-human evaluation (soft ECoG in epilepsy surgery) published, 26 papers and 29 patents.”
  • “Lamp on sale in the EU ("Order Now"), validated by European hospitals according to the company; number of users not published.”
If it works
Clinical introductions to epilepsy centres and a possible joint observational study.
First step
Ask Neurosoft's CEO which centres they work with and request one introduction.

Route lamp alerts into TIBOK's monitored chronic-care pathway

Lampsy alerts caregivers but has no clinical follow-up layer; TIBOK's AI assistant Eva monitors readings and alerts or calls back, and TIBOK connects devices by Bluetooth. Integrating seizure events into TIBOK gives Lampsy a care pathway sold to clinics and insurers, and TIBOK a neurology use case.

20%confidence

Evidence from the records

  • “connected devices (Apple Health, Android Health Connect, direct Bluetooth, or a simple photo of a screen)”
  • “monitors every reading, reminds, alerts and calls back”
  • “AI analyzes the lamp's sensor signals to detect epileptic seizures without contact and alert caregivers.”
If it works
A distributable 'night seizure monitoring' offer through TIBOK's clinic and insurer clients.
First step
Exchange API specs to send a seizure event into a TIBOK patient record.

Investors1

A fund whose thesis fits

Approach Mutua Ventures through Legit.Health

Mutua Ventures is the HealthTech/FinTech CVC of a Spanish insurer active in Spain and Europe; an insurer investor could also pilot reimbursement. It led a Legit.Health round in the network, offering a warm introduction.

25%confidence

Evidence from the records

  • “Mutua Madrileña (Mutua Ventures, lead), Wayra (Telefónica), Grupo Ribera, business angels”
  • “€230K (one source mentions a $1M seed, inconsistent)”
If it works
A seed investment plus an Iberian insurer pilot.
First step
Ask Legit.Health's founders for an intro to Mutua Ventures.

Peers1

Founders solving the same problem elsewhere

Learn from Legit.Health's medical-device certification path

Legit.Health took an AI medical device through CE marking with an ISO 13485 quality system in Iberia; Lampsy faces the same regulatory steps. A founder exchange shortens the learning curve.

30%confidence

Evidence from the records

  • “CE-marked medical device (ISO 13485), with partners listed such as NHS, SERMAS, SESPA, Sanitas, Adeslas, Novartis and Almirall.”
  • “Medium-to-high risk: clinical validation, regulatory status and little funding raised.”
If it works
Faster, cheaper certification planning.
First step
Request a 30-minute call with Legit.Health's regulatory lead.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Corporate venture arm of Spanish insurer Mutua Madrileña, investing in health and fintech; led Legit.Health's 2024 round.

Portuguese epilepsy detection — Iberian medtech; Fundação Ageas (insurer foundation) already backs it.

45%confidence

Evidence from the records

  • “"HealthTech"”
  • “Epileptic seizure detection”
  • “Lamp on sale in the EU ("Order Now"), validated by European hospitals according to the company”
Intro path
Founder-to-founder intro via Legit.Health (network portfolio company of Mutua Ventures (Mutua Madrileña)).
First step
Ask Fundação Ageas contacts for intro.

Boston fund investing only in PharmStars accelerator graduates: pharma-ready digital health, first 12 deals in rare-disease digital health.

Epileptic-seizure detection lamp on sale in the EU: a digital biomarker for a neurological condition that anti-epileptic drug makers could use in trials or patient support.

45%confidence

Evidence from the records

  • “Epileptic seizure detection”
  • “Lamp on sale in the EU”
First step
Propose a PharmStars application framed around pharma trial endpoints.

Zero-equity nonprofit accelerator (since 2009) running corporate-funded programmes in Boston, Dallas, Jerusalem, Lausanne and London.

Portuguese epilepsy monitoring — Lausanne/Switzerland health programme fit.

40%confidence

Evidence from the records

  • “"Switzerland"”
  • “Epileptic seizure detection”
  • “Lamp on sale in the EU ("Order Now"), validated by European hospitals according to the company”
Intro path
Founder-to-founder intro via Monte Caldera Technologies Inc. (network portfolio company of MassChallenge).
First step
Apply to MassChallenge Switzerland.

Spanish healthcare corporate investor whose only known venture deal is dermatology AI company Legit.Health.

Portuguese epileptic-seizure detection device — Iberian medtech at pre-seed with EIC backing.

40%confidence

Evidence from the records

  • “Legit.Health”
  • “Epileptic seizure detection”
  • “Lamp on sale in the EU ("Order Now"), validated by European hospitals according to the company”
Intro path
Founder-to-founder intro via Legit.Health (network portfolio company of Grupo Ribera).
First step
Propose a clinical validation site in Spain.

US investor with no profile in our data; participated in Neurosoft Bioelectronics' oversubscribed $7.5M seed.

Portuguese seizure-detection device — neurology medtech.

25%confidence

Evidence from the records

  • “Seed (oversubscribed)”
  • “Epileptic seizure detection”
  • “Lamp on sale in the EU ("Order Now"), validated by European hospitals according to the company”
Intro path
Founder-to-founder intro via Neurosoft Bioelectronics (network portfolio company of IAG Capital Partners).
First step
Low priority.

Vienna's university high-tech incubator (University of Vienna, TU Wien) running SCALEup, Health Hub Vienna and other programmes for Austrian deep tech.

Portuguese seizure-detection medtech — Health Hub Vienna could host EU expansion; requires Vienna presence.

25%confidence

Evidence from the records

  • “Health Hub Vienna”
  • “Epileptic seizure detection”
  • “Lamp on sale in the EU ("Order Now"), validated by European hospitals according to the company”
Intro path
Founder-to-founder intro via Deepentix (network portfolio company of INiTS).
First step
Check Health Hub Vienna eligibility for foreign startups.

Swiss innovation agency funding Swiss startups; supported Neurosoft Bioelectronics through its Swiss Accelerator grant.

Portuguese seizure detection — medtech; needs Swiss entity.

15%confidence

Evidence from the records

  • “Switzerland”
  • “Epileptic seizure detection”
  • “Lamp on sale in the EU ("Order Now"), validated by European hospitals according to the company”
Intro path
Founder-to-founder intro via Neurosoft Bioelectronics (network portfolio company of Innosuisse).
First step
Low priority.

Investment analysis

4.5D

Grade D

Rank 63 of 151

Disruption5.0/10
Business model4.0/10
Market4.0/10
Risk(lower is better)6.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Useful product, but its scale is still unknown: too early.

Disruption

5/10

Smart lamp for epileptic seizure detection: a new use in an existing device category.

Business model

4/10

On sale in the EU, number of users not published.

Market

4/10

TAM $0.662bn → base 3; scalability 5/10 (neutral); international: sales in the EU and validation by European hospitals (+1) → 4/10.

Risk

6/10

Lower is better

Medium-to-high risk: clinical validation, regulatory status and little funding raised.

Strengths

  • Product on sale
  • Academic spin-off

Risks

  • Narrow niche
  • Users not published

Funding

$680K, disclosed
  1. non daté

    angel€50K

    Angels Way

  2. 2025-05-09

    pre-seed€230K

    Fundação Ageas (lead), business angels Susana de Sousa and Ellie Asgari

  3. non daté

    EU program€350K (program, according to KPMG)

    European program supported by KPMG / EIC (CORDIS 101310739)

  4. 2024

    prizenot specified

    Inova+ Prize 2024; Epilepsy Foundation Shark Tank 2024

  5. 2026-09

    prizenot specified

    KPMG Tech Innovator Portugal (6th edition)

  6. 2025-2026

    seed (announced)~€1M planned / $1M according to Signalbase

    not confirmed

Amount used in the study. €280K private + €350K EU program; announced ~€1M seed (not confirmed) as upper bound.

Note. ~€280K private (€230K + €50K) + grants; one source (Signalbase) mentions a $1M/€1M seed, not confirmed

SWC Portugal 2026 qualification confirmed by RTP ("Lampsy Health apura-se para a Startup World Cup"); Joana Pinto confirmed as CTO by KPMG; winner of KPMG Global Tech Innovator Portugal 2026 (international final at Web Summit).

Team

  • Vicente Garção

    Co-founder

    Biomedical engineer, PhD candidate at Instituto Superior Técnico (Lisbon).

  • Leonor Pereira

    Co-founder

    Instituto Superior Técnico alumna (biomedical engineering).

  • Joana Pinto

    Co-founder & CTO

    Técnico alumna; former co-founder of Clynx Health.

Sources

Regional final
Portugal 2026 (Startup World Cup Portugal, Unicorn Factory Lisboa, 17-18 June 2026) – qualification reported by RTP Geração Digital
Identification confidence
high
Founding year: 2024 (medium confidence)
"Founded 2024" according to Village.ai/PremierAlts; IST spin-off presented at Lab2Market 2024. village.ai
  1. 1dn.pt/fazedores/lampsy-vigia-epilepsia-com-ia-num-candeeiro
  2. 2ecosistemastartup.com/lampsy-health-cierra-230000e-para-lamparas-antiepilepticas
  3. 3kpmg.com/pt/pt/noticias-media/comunicados-de-imprensa/2026/09/lampsy
  4. 4rtp.pt/play/p4068/e938628/geracao-digital

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet